作者
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen Anthony Strickland, Donna Hogge, Scott R Solomon, Richard M Stone, Dale L Bixby, Jonathan E Kolitz, Gary J Schiller, Matthew Joseph Wieduwilt, Daniel H Ryan, Antje Hoering, Michael Chiarella, Arthur Chin Louie, Bruno C Medeiros
发表日期
2016/5/20
来源
Journal of Clinical Oncology
卷号
34
期号
15_suppl
页码范围
7000-7000
出版商
American Society of Clinical Oncology
简介
7000
Background: Older patients with secondary AML have poor outcomes following first-line cytarabine and anthracycline-based treatment. CPX-351 is a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar ratio with enhanced efficacy among poor risk AML patients. We report final results from a randomized open-label study of first-line CPX-351 in patients with high-risk sAML (NCT01696084). Methods: Patients 60-75 years of age with untreated AML with a history of prior cytotoxic treatment, antecedent MDS or CMML (+/- prior hypomethylator treatment), or AML with WHO-defined MDS-related cytogenetic abnormalities were eligible. 300 patients were to be randomized 1:1 to CPX-351 (100 units/m2, days 1, 3, 5) or 7+3 (cytarabine 100 mg/m2/day x 7 days, daunorubicin 60 mg/m2 days 1, 2, 3) induction therapy. Endpoints included: overall (OS, 1o) and event free survival (EFS …
学术搜索中的文章
JE Lancet, GL Uy, JE Cortes, LF Newell, TL Lin… - 2016